Recent advances in the treatment of hyperammonemia

Advanced Drug Delivery Reviews

Volumn 90, Issue , 2015, Pages 55-68

  Matoori, Simon ^a   Leroux, Jean Christophe ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Ammonia; Cirrhosis; Hepatic encephalopathy; Liver failure; Metabolic disorders; Urea cycle

Indexed keywords

AMINO ACIDS; DETOXIFICATION; DRUG DELIVERY; METABOLISM; NEURODEGENERATIVE DISEASES; UREA;

AMMONIA PRODUCTION; CIRRHOSIS; HEPATIC ENCEPHALOPATHIES; LIVER FAILURE; METABOLIC DISORDERS; METABOLIC TRANSFORMATIONS; PHARMACOLOGICAL TREATMENT; SYNERGISTIC COMBINATIONS;

AMMONIA;

4 PHENYLBUTYRIC ACID; AMMONIA; ANTIBIOTIC AGENT; ARGININE; AST 120; BENZOIC ACID PLUS PHENYLACETIC ACID; BRANCHED CHAIN AMINO ACID; CARGLUMIC ACID; CITRULLINE; GLUTAMINASE; GLYCEROL PHENYLBUTYRATE; LACTITOL; LACTULOSE; MACROGOL 3350; METFORMIN; NEOMYCIN; ORNITHINE ASPARTATE; ORNITHINE PHENYLACETATE; PROBIOTIC AGENT; RIFAXIMIN; VSL3;

BIOARTIFICIAL LIVER; CELL THERAPY; DETOXIFICATION; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; ENZYME INHIBITION; GENE THERAPY; HEMODIALYSIS; HEMOFILTRATION; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; LIVER REGENERATION; META ANALYSIS (TOPIC); NONHUMAN; PERITONEAL DIALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UREA CYCLE; ANIMAL; DRUG INACTIVATION; METABOLISM;

AMMONIA; ANIMALS; HUMANS; HYPERAMMONEMIA; INACTIVATION, METABOLIC;

EID: 84939563610     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.04.009     Document Type: Review

References (170)

1. Stewart C.A., Smith G.E. Minimal hepatic encephalopathy. Nat. Clin. Pract. Gastroenterol. Hepatol. 2007, 4:677-685.
2. Prakash R., Mullen K.D. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:515-525.
3. Bosoi C.R., Rose C.F. Identifying the direct effects of ammonia on the brain. Metab. Brain Dis. 2009, 24:95-102.
4. Bromberg P.A., Robin E.D., Forkner C.E. The existence of ammonia in blood in vivo with observations on the significance of the NH4 plus minus NH3 system. J. Clin. Invest. 1960, 39:332-341.
5. Ott P., Vilstrup H. Cerebral effects of ammonia in liver disease: current hypotheses. Metab. Brain Dis. 2014, 29:901-911.
6. Jahn T.P., Møller A.L.B., Zeuthen T., Holm L.M., Klaerke D.A., Mohsin B., Kühlbrandt W., Schjoerring J.K. Aquaporin homologues in plants and mammals transport ammonia. FEBS Lett. 2004, 574:31-36.
7. 2 channel in the human red cell membrane. FASEB J. 2008, 22:64-73.
8. Zidi-Yahiaoui N., Mouro-Chanteloup I., D'Ambrosio A., Lopez C., Gane P., Le Van Kim C., Cartron J.P., Colin Y., Ripoche P. Hum. Rhesus B Rhesus C glycoproteins 2005, 391:33-40.
9. Keiding S., Sørensen M., Bender D., Munk O.L., Ott P., Vilstrup H. Brain metabolism of 13N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology 2006, 43:42-50.
10. Felipo V. Hepatic encephalopathy: effects of liver failure on brain function. Nat. Rev. Neurosci. 2013, 14:851-858.
11. Rangroo Thrane V., Thrane A.S., Wang F., Cotrina M.L., Smith N.A., Chen M., Xu Q., Kang N., Fujita T., Nagelhus E.A., Nedergaard M. Ammonia triggers neuronal disinhibition and seizures by impairing astrocyte potassium buffering. Nat. Med. 2013, 19:1643-1648.
12. Romero-Gómez M., Jover M., Galán J.J., Ruiz A. Gut ammonia production and its modulation. Metab. Brain Dis. 2009, 24:147-157.
13. Wright G., Noiret L., Olde Damink S.W.M., Jalan R. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies. Liver Int. 2011, 31:163-175.
14. Jalan R., Wright G., Davies N.A., Hodges S.J. l-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med. Hypotheses 2007, 69:1064-1069.
15. Chatauret N., Desjardins P., Zwingmann C., Rose C., Rao K.V.R., Butterworth R.F. Direct molecular and spectroscopic evidence for increased ammonia removal capacity of skeletal muscle in acute liver failure. J. Hepatol. 2006, 44:1083-1088.
16. Labow B.I., Souba W.W., Abcouwer S.F. Mechanisms governing the expression of the enzymes of glutamine metabolism-glutaminase and glutamine synthetase. J. Nutr. 2001, 131:2467S-2474S.
17. Olde Damink S.W.M., Jalan R., Redhead D.N., Hayes P.C., Deutz N.E.P., Soeters P.B. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002, 36:1163-1171.
18. Olde Damink S.W.M., Jalan R., Deutz N.E.P., Redhead D.N., Dejong C.H.C., Hynd P., Jalan R.A., Hayes P.C., Soeters P.B. The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. Hepatology 2003, 37:1277-1285.
19. Häberle J. Clinical and biochemical aspects of primary and secondary hyperammonemic disorders. Arch. Biochem. Biophys. 2013, 536:101-108.
20. Vilstrup H., Amodio P., Bajaj J., Cordoba J., Ferenci P., Mullen K.D., Weissenborn K., Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014, 60:715-735.
21. Häberle J., Boddaert N., Burlina A., Chakrapani A., Dixon M., Huemer M., Karall D., Martinelli D., Crespo P.S., Santer R., Servais A., Valayannopoulos V., Lindner M., Rubio V., Dionisi-Vici C. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J. Rare Dis. 2012, 7:32.
22. Heitink-Pollé K.M.J., Prinsen B.H., de Koning T.J., van Hasselt P.M., Bierings M.B. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase. JIMD Rep. 2013, 7:103-108.
23. Summar M.L., Koelker S., Freedenberg D., Le Mons C., Haberle J., Lee H.-S., Kirmse B. The incidence of urea cycle disorders. Mol. Genet. Metab. 2013, 110:179-180.
24. Bismuth M., Funakoshi N., Cadranel J.-F., Blanc P. Hepatic encephalopathy: from pathophysiology to therapeutic management. Eur. J. Gastroenterol. Hepatol. 2011, 23:8-22.
25. Stepanova M., Mishra A., Venkatesan C., Younossi Z.M. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin. Gastroenterol. Hepatol. 2012, 10:1034-1041. (e1).
26. Patil D.H., Westaby D., Mahida Y.R., Palmer K.R., Rees R., Clark M.L., Dawson A.M., Silk D.B. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy. Gut 1987, 28:255-259.
27. Vince A.J., Burridge S.M. Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J. Med. Microbiol. 1980, 13:177-191.
28. Weber F.L., Banwell J.G., Fresard K.M., Cummings J.H. Nitrogen in fecal bacterial, fiber, and soluble fractions of patients with cirrhosis: effects of lactulose and lactulose plus neomycin. J. Lab. Clin. Med. 1987, 110:259-263.
29. Mortensen P.B. The effect of oral-administered lactulose on colonic nitrogen metabolism and excretion. Hepatology 1992, 16:1350-1356.
30. Rahimi R.S., Singal A.G., Cuthbert J.A., Rockey D.C. Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern. Med. 2014, 174:1727-1733.
31. Kot T.V., Pettit-Young N.A. Lactulose in the management of constipation: a current review. Ann. Pharmacother. 1992, 26:1277-1282.
32. Leise M.D., Poterucha J.J., Kamath P.S., Kim W.R. Management of hepatic encephalopathy in the hospital. Mayo Clin. Proc. 2014, 89:241-253.
33. Als-Nielsen B., Gluud L.L., Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004, 328:1046.
34. Prasad S., Dhiman R.K., Duseja A., Chawla Y.K., Sharma A., Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007, 45:549-559.
35. Sharma P., Sharma B.C., Agrawal A., Sarin S.K. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J. Gastroenterol. Hepatol. 2012, 27:1329-1335.
36. Agrawal A., Sharma B.C., Sharma P., Sarin S.K. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am. J. Gastroenterol. 2012, 107:1043-1050.
37. Kimer N., Krag A., Gluud L.L. Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Prefer. Adherence. 2014, 8:331-338.
38. Blanc P., Daures J.-P., Rouillon J.-M., Peray P., Pierrugues R., Larrey D., Gremy F., Michel H. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 1992, 15:222-228.
39. Morgan M.Y., Hawley K.E. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 1987, 7:1278-1284.
40. Macbeth W.A.G., Kass E., Mcdermott W. Treatment of hepatic encephalopathy by alteration of intestinal flora with Lactobacillus acidophilus. Lancet 1965, 285:399-403.
41. Vince A., Dawson A.M., Park N., O'Grady F. Ammonia production by intestinal bacteria. Gut 1973, 14:171-177.
42. Bajaj J.S., Ridlon J.M., Hylemon P.B., Thacker L.R., Heuman D.M., Smith S., Sikaroodi M., Gillevet P.M. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G168-G175.
43. Bajaj J.S., Heuman D.M., Hylemon P.B., Sanyal A.J., White M.B., Monteith P., Noble N.A., Unser A.B., Daita K., Fisher A.R., Sikaroodi M., Gillevet P.M. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J. Hepatol. 2014, 60:940-947.
44. Conn H.O., Leevy C.M., Vlahcevic Z., Rodgers J.B., Maddrey W.C., Seeff L., Levy L.L. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. Gastroenterology 1977, 72:573-583.
45. Last P.M., Sherlock S. Systemic absorption of orally administered neomycin in liver disease. N. Engl. J. Med. 1960, 262:385-389.
46. Hoover W.W., Gerlach E.H., Hoban D.J., Eliopoulos G.M., Pfaller M.A., Jones R.N. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn. Microbiol. Infect. Dis. 1993, 16:111-118.
47. Marchi E., Mascellani G., Montecchi L., Venturini A.P., Brufani M., Cellai L. 4-Deoxypyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J. Med. Chem. 1985, 28:960-963.
48. Descombe J.J., Dubourg D., Picard M., Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int. J. Clin. Pharmacol. Res. 1994, 14:51-56.
49. Huang D.B., DuPont H.L. Rifaximin-a novel antimicrobial for enteric infections. J. Infect. 2005, 50:97-106.
50. Bucci L., Palmieri G.C. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr. Med. Res. Opin. 1993, 13:109-118.
51. Pedretti G., Calzetti C., Missale G., Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital. J. Gastroenterol. 1991, 23:175-178.
52. Mas A., Rodés J., Sunyer L., Rodrigo L., Planas R., Vargas V., Castells L., Rodríguez-Martínez D., Fernández-Rodríguez C., Coll I., Pardo A. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J. Hepatol. 2003, 38:51-58.
53. Bass N.M., Mullen K.D., Sanyal A., Poordad F., Neff G., Leevy C.B., Sigal S., Sheikh M.Y., Beavers K., Frederick T., Teperman L., Hillebrand D., Huang S., Merchant K., Shaw A., Bortey E., Forbes W.P. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 2010, 362:1071-1081.
54. Sharma B.C., Sharma P., Lunia M.K., Srivastava S., Goyal R., Sarin S.K. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am. J. Gastroenterol. 2013, 108:1458-1463.
55. Kimer N., Krag A., Møller S., Bendtsen F., Gluud L.L. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment. Pharmacol. Ther. 2014, 40:123-132.
56. Huang E., Esrailian E., Spiegel B.M.R. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Aliment. Pharmacol. Ther. 2007, 26:1147-1161.
57. Dai C., Jiang M., Sun M.-J. Letter: the effects of rifaximin in hepatic encephalopathy. Aliment. Pharmacol. Ther. 2014, 40:857-858.
58. Bajaj J.S., Riggio O. Drug therapy: rifaximin. Hepatology 2010, 52:1484-1488.
59. Blandizzi C., Viscomi G.C., Marzo A., Scarpignato C. Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. Pharmacol. Res. 2014, 85:39-44.
60. Viscomi G.C., Campana M., Barbanti M., Grepioni F., Polito M., Confortini D., Rosini G., Righi P., Cannata V., Braga D. Crystal forms of rifaximin and their effect on pharmaceutical properties. CrystEngComm 2008, 10:1074-1081.
61. Farrell D.J. Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?. J. Clin. Gastroenterol. 2013, 47:205-211.
62. Schrezenmeir J., de Vrese M. Probiotics, prebiotics, and synbiotics-approaching a definition. Am. J. Clin. Nutr. 2001, 73:361S-364S.
63. Zhang Z., Zhai H., Geng J., Yu R., Ren H., Fan H., Shi P. Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing. Am. J. Gastroenterol. 2013, 108:1601-1611.
64. McGee R.G., Bakens A., Wiley K., Riordan S.M., Webster A.C. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst. Rev. 2011, 11:CD008716.
65. Lunia M.K., Sharma B.C., Sharma P., Sachdeva S., Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin. Gastroenterol. Hepatol. 2014, 12:1003-1008. (e1).
66. Chapman T.M., Plosker G.L., Figgitt D.P. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. Drugs 2006, 66:1371-1387.
67. Dhiman R.K., Rana B., Agrawal S., Garg A., Chopra M., Thumburu K.K., Khattri A., Malhotra S., Duseja A., Chawla Y.K. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 2014, 147:1327-1337. (e3).
68. Bajaj J.S., Heuman D.M., Hylemon P.B., Sanyal A.J., Puri P., Sterling R.K., Luketic V., Stravitz R.T., Siddiqui M.S., Fuchs M., Thacker L.R., Wade J.B., Daita K., Sistrun S., White M.B., Noble N.A., Thorpe C., Kakiyama G., Pandak W.M., Sikaroodi M., Gillevet P.M. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment. Pharmacol. Ther. 2014, 39:1113-1125.
69. Kankainen M., Paulin L., Tynkkynen S., von Ossowski I., Reunanen J., Partanen P., Satokari R., Vesterlund S., Hendrickx A.P., Lebeer S., De Keersmaecker S.C., Vanderleyden J., Hämäläinen T., Laukkanen S., Salovuori N., Ritari J., Alatalo E., Korpela R., Mattila-Sandholm T., Lassig A., Hatakka K., Kinnunen K.T., Karjalainen H., Saxelin M., Laakso K., Surakka A., Palva A., Salusjärvi T., Auvinen P., de Vos W.M. Comparative genomic analysis of Lactobacillus rhamnosus GG reveals pili containing a human-mucus binding protein. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:17193-17198.
70. Enns G.M., Berry S.A., Berry G.T., Rhead W.J., Brusilow S.W., Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N. Engl. J. Med. 2007, 356:2282-2292.
71. Mokhtarani M., Diaz G.A., Rhead W., Berry S.A., Lichter-Konecki U., Feigenbaum A., Schulze A., Longo N., Bartley J., Berquist W., Gallagher R., Smith W., McCandless S.E., Harding C., Rockey D.C., Vierling J.M., Mantry P., Ghabril M., Brown R.S., Dickinson K., Moors T., Norris C., Coakley D., Milikien D.A., Nagamani S.C., Lemons C., Lee B., Scharschmidt B.F. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. Mol. Genet. Metab. 2013, 110:446-453.
72. Webster L.T., Siddiqui U.A., Lucas S.V., Strong J.M., Mieyal J.J. Identification of separate acyl- CoA:glycine and acyl-CoA:L-glutamine N-acyltransferase activities in mitochondrial fractions from liver of rhesus monkey and man. J. Biol. Chem. 1976, 251:3352-3358.
73. Schwab A.J., Tao L., Yoshimura T., Simard A., Barker F., Pang K.S. Hepatic uptake and metabolism of benzoate: a multiple indicator dilution, perfused rat liver study. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 280:G1124-G1136.
74. Barshop B.A., Breuer J., Holm J., Leslie J., Nyhan W.L. Excretion of hippuric acid during sodium benzoate therapy in patients with hyperglycinaemia or hyperammonaemia. J. Inherit. Metab. Dis. 1989, 12:72-79.
75. Kikuchi G., Motokawa Y., Yoshida T., Hiraga K. Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 2008, 84:246-263.
76. James M.O., Smith R.L., Williams R.T., Reidenberg M. The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species. Proc. R. Soc. B Biol. Sci. 1972, 182:25-35.
77. Moldave K., Meister A. Synthesis of phenylacetylglutamine by human tissue. J. Biol. Chem. 1957, 229:463-476.
78. Darmaun D., Welch S., Rini A., Sager B.K., Altomare A., Haymond M.W. Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism. Am. J. Physiol. Endocrinol. Metab. 1998, 274:E801-E807.
79. Ytrebø L.M., Kristiansen R.G., Maehre H., Fuskevåg O.M., Kalstad T., Revhaug A., Cobos M.J., Jalan R., Rose C.F. l-Ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology 2009, 50:165-174.
80. Kristiansen R.G., Rose C.F., Fuskevåg O.-M., Mæhre H., Revhaug A., Jalan R., Ytrebø L.M. l-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 307:G1024-G1031.
81. Batshaw M.L., MacArthur R.B., Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J. Pediatr. 2001, 138:S46-S55.
82. Newmark H.L., Young C.W. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J. Cell. Biochem. 1995, 59:247-253.
83. Guffon N., Kibleur Y., Copalu W., Tissen C., Breitkreutz J. Developing a new formulation of sodium phenylbutyrate. Arch. Dis. Child. 2012, 97:1081-1085.
84. McGuire B.M., Zupanets I.A., Lowe M.E., Xiao X., Syplyviy V.A., Monteleone J., Gargosky S., Dickinson K., Martinez A., Mokhtarani M., Scharschmidt B.F. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 2010, 51:2077-2085.
85. Diaz G.A., Krivitzky L.S., Mokhtarani M., Rhead W., Bartley J., Feigenbaum A., Longo N., Berquist W., Berry S.A., Gallagher R., Lichter-Konecki U., Bartholomew D., Harding C.O., Cederbaum S., McCandless S.E., Smith W., Vockley G., Bart S.A., Korson M.S., Kronn D., Zori R., Merritt J.L., Nagamani S.C.S., Mauney J., Lemons C., Dickinson K., Moors T.L., Coakley D.F., Scharschmidt B.F., Lee B. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology 2013, 57:2171-2179.
86. Guha M. Urea cycle disorder drug approved. Nat. Biotechnol. 2013, 31:274.
87. Rockey D.C., Vierling J.M., Mantry P., Ghabril M., Brown R.S., Alexeeva O., Zupanets I.A., Grinevich V., Baranovsky A., Dudar L., Fadieienko G., Kharchenko N., Klaryts'ka I., Morozov V., Grewal P., McCashland T., Reddy K.G., Reddy K.R., Syplyviy V., Bass N.M., Dickinson K., Norris C., Coakley D., Mokhtarani M., Scharschmidt B.F. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 2014, 59:1073-1083.
88. Rose C., Michalak A., Pannunzio P., Therrien G., Quack G., Kircheis G., Butterworth R.F. l-Ornithine-l-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab. Brain Dis. 1998, 13:147-157.
89. Jover-Cobos M., Noiret L., Lee K., Sharma V., Habtesion A., Romero-Gomez M., Davies N., Jalan R. Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats. J. Hepatol. 2014, 60:545-553.
90. Rose C., Michalak A., Rao K.V., Quack G., Kircheis G., Butterworth R.F. l-Ornithine-l-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 1999, 30:636-640.
91. Alvares-da-Silva M.R., de Araujo A., Vicenzi J.R., da Silva G.V., Oliveira F.B., Schacher F., Oliboni L., Magnus A., Kruel L.P., Prieb R., Fernandes L.N. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled trial. Hepatol. Res. 2014, 44:956-963.
92. Mittal V.V., Sharma B.C., Sharma P., Sarin S.K. A randomized controlled trial comparing lactulose, probiotics, and l-ornithine l-aspartate in treatment of minimal hepatic encephalopathy. Eur. J. Gastroenterol. Hepatol. 2011, 23:725-732.
93. Kircheis G., Nilius R., Held C., Berndt H., Buchner M., Görtelmeyer R., Hendricks R., Krüger B., Kuklinski B., Meister H., Otto H.J., Rink C., Rösch W., Stauch S. Therapeutic efficacy of l-ornithine-l-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997, 25:1351-1360.
94. Stauch S., Kircheis G., Adler G., Beckh K., Ditschuneit H., Görtelmeyer R., Hendricks R., Heuser A., Karoff C., Malfertheiner P., Mayer D., Rösch W., Steffens J. Oral l-ornithine-l-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J. Hepatol. 1998, 28:856-864.
95. Jiang Q., Jiang X.H., Zheng M.H., Chen Y.P. l-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis. J. Gastroenterol. Hepatol. 2009, 24:9-14.
96. Zhu G.Q., Shi K.Q., Huang S., Wang L.R., Lin Y.Q., Huang G.Q., Chen Y.P., Braddock M., Zheng M.H. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Aliment. Pharmacol. Ther. 2015, 41:624-635.
97. Bai M., He C., Yin Z., Niu J., Wang Z., Qi X., Liu L., Yang Z., Guo W., Tie J., Bai W., Xia J., Cai H., Wang J., Wu K., Fan D., Han G. Randomised clinical trial: l-ornithine-l-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS. Aliment. Pharmacol. Ther. 2014, 40:63-71.
98. Acharya S.K., Bhatia V., Sreenivas V., Khanal S., Panda S.K. Efficacy of l-ornithine l-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009, 136:2159-2168.
99. Rose C.F. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin. Pharmacol. Ther. 2012, 92:321-331.
100. Ventura-Cots M., Arranz J.A., Simón-Talero M., Torrens M., Blanco A., Riudor E., Fuentes I., Suñé P., Soriano G., Córdoba J. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study. J. Clin. Gastroenterol. 2013, 47:881-887.
101. Daniotti M., la Marca G., Fiorini P., Filippi L. New developments in the treatment of hyperammonemia: emerging use of carglumic acid. Int. J. Gen. Med. 2011, 4:21-28.
102. Häberle J. Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency. Ther. Clin. Risk Manag. 2011, 7:327-332.
103. Kasapkara C.S., Kanğin M., Taş F.F., Topçu Y., Demir R., Ozbek M.N. Unusual cause of hyperammonemia in two cases with short-term and long-term valproate therapy successfully treated by single dose carglumic acid. J. Pediatr. Neurosci. 2013, 8:250-252.
104. Holecek M. Branched-chain amino acids and ammonia metabolism in liver disease: therapeutic implications. Nutrition 2013, 29:1186-1191.
105. Dam G., Keiding S., Munk O.L., Ott P., Buhl M., Vilstrup H., Bak L.K., Waagepetersen H.S., Schousboe A., Møller N., Sørensen M. Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301:G269-G277.
106. Marchesini G., Dioguardi F., Bianchi G., Zoli M., Bellati G., Roffi L., Martines D., Abbiati R. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. J. Hepatol. 1990, 11:92-101.
107. Gluud L.L., Dam G., Borre M., Les I., Cordoba J., Marchesini G., Aagaard N.K., Risum N., Vilstrup H. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J. Nutr. 2013, 143:1263-1268.
108. Als-Nielsen B., Koretz R.L., Kjaergard L.L., Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst. Rev. 2003, CD001939.
109. Freund H., Hoover H.C., Atamian S., Fischer J.E. Infusion of the branched chain amino acids in postoperative patients. Anticatabolic properties. Ann. Surg. 1979, 190:18-23.
110. Nair K.S., Schwartz R.G., Welle S. Leucine as a regulator of whole body and skeletal muscle protein metabolism in humans. Am. J. Physiol. 1992, 263:E928-E934.
111. Hanai T., Shiraki M., Nishimura K., Ohnishi S., Imai K., Suetsugu A., Takai K., Shimizu M., Moriwaki H. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition 2015, 31:193-199.
112. Montet J.-C., Salmon L., Caroli-Bosc F.X., Demarquay J.F., Montet A.M., Delmont J.P. l-Arginine infusion protects against hyperammonemia and hepatic encephalopathy in cirrhotic patients with variceal haemorrhage. Gastroenterology 2000, 118:A978.
113. Malaguarnera M. Acetyl-l-carnitine in hepatic encephalopathy. Metab. Brain Dis. 2013, 28:193-199.
114. Jiang Q., Jiang G., Shi K., Cai H., Wang Y., Zheng M. Oral acetyl-l-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Ann. Hepatol. 2013, 12:803-809.
115. Gidal B.E., Inglese C.M., Meyer J.F., Pitterle M.E., Antonopolous J., Rust R.S. Diet- and valproate-induced transient hyperammonemia: effect of l-carnitine. Pediatr. Neurol. 1997, 16:301-305.
116. Rebouche C.J. Kinetics, pharmacokinetics, and regulation of l-carnitine and acetyl-l-carnitine metabolism. Ann. N. Y. Acad. Sci. 2004, 1033:30-41.
117. Riggio O., Merli M., Capocaccia L., Caschera M., Zullo A., Pinto G., Gaudio E., Franchitto A., Spagnoli R., D'aquilino E., Seri S., Moretti R., Cantafora A. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology 1992, 16:785-789.
118. Reding P., Duchateau J., Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet 1984, 2:493-495.
119. Takuma Y., Nouso K., Makino Y., Hayashi M., Takahashi H. Clinical trial: oral zinc in hepatic encephalopathy. Aliment. Pharmacol. Ther. 2010, 32:1080-1090.
120. Katayama K., Saito M., Kawaguchi T., Endo R., Sawara K., Nishiguchi S., Kato A., Kohgo H., Suzuki K., Sakaida I., Ueno Y., Habu D., Ito T., Moriwaki H., Suzuki K. Effect of zinc on liver cirrhosis with hyperammonemia: a preliminary randomized, placebo-controlled double-blind trial. Nutrition 2014, 30:1409-1414.
121. Chavez-Tapia N.C., Cesar-Arce A., Barrientos-Gutiérrez T., Villegas-López F.A., Méndez-Sanchez N., Uribe M. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr. J. 2013, 12:74.
122. Jalan R., Kapoor D. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. Gut 2003, 52:1041-1045.
123. Jalan R., Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin. Sci. (Lond.) 2004, 106:467-474.
124. Mitzner S.R. Extracorporeal liver support-albumin dialysis with the Molecular Adsorbent Recirculating System (MARS). Ann. Hepatol. 2011, 10(Suppl. 1):S21-S28.
125. Bañares R., Catalina M.-V., Vaquero J. Molecular adsorbent recirculating system and bioartificial devices for liver failure. Clin. Liver Dis. 2014, 18:945-956.
126. Khuroo M.S., Khuroo M.S., Farahat K.L.C. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl. 2004, 10:1099-1106.
127. Bañares R., Nevens F., Larsen F.S., Jalan R., Albillos A., Dollinger M., Saliba F., Sauerbruch T., Klammt S., Ockenga J., Pares A., Wendon J., Brünnler T., Kramer L., Mathurin P., de la Mata M., Gasbarrini A., Müllhaupt B., Wilmer A., Laleman W., Eefsen M., Sen S., Zipprich A., Tenorio T., Pavesi M., Schmidt H.H., Mitzner S., Williams R., Arroyo V. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013, 57:1153-1162.
128. Saliba F., Camus C., Durand F., Mathurin P., Letierce A., Delafosse B., Barange K., Perrigault P.F., Belnard M., Ichaï P., Samuel D. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann. Intern. Med. 2013, 159:522-531.
129. Sauer I.M., Goetz M., Steffen I., Walter G., Kehr D.C., Schwartlander R., Hwang Y.J., Pascher A., Gerlach J.C., Neuhaus P. In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology 2004, 39:1408-1414.
130. Stange J., Mitzner S.R., Risler T., Erley C.M., Lauchart W., Goehl H., Klammt S., Peszynski P., Freytag J., Hickstein H., Löhr M., Liebe S., Schareck W., Hopt U.T., Schmidt R. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif. Organs 1999, 23:319-330.
131. Sorkine P., Ben Abraham R., Szold O., Biderman P., Kidron A., Merchav H., Brill S., Oren R. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit. Care Med. 2001, 29:1332-1336.
132. Schmidt L.E., Svendsen L.B., Sørensen V.R., Hansen B.A., Larsen F.S. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl. 2001, 7:709-712.
133. Novelli G., Rossi M., Pretagostini R., Poli L., Novelli L., Berloco P., Ferretti G., Iappelli M., Cortesini R. MARS (Molecular Adsorbent Recirculating System): experience in 34 cases of acute liver failure. Liver Int. 2002, 22:43-47.
134. Al-Chalabi A., Matevossian E., A.-K.v, Thaden P.Luppa, Neiss A., Schuster T., Yang Z., Schreiber C., Schimmel P., Nairz E., Perren A., Radermacher P., Huber W., Schmid R.M., Kreymann B. Evaluation of the Hepa Wash® treatment in pigs with acute liver failure. BMC Gastroenterol. 2013, 13:83.
135. Sentürk E., Esen F., Ozcan P.E., Rifai K., Pinarbaşi B., Cakar N., Telci L. The treatment of acute liver failure with fractionated plasma separation and adsorption system: experience in 85 applications. J. Clin. Apher. 2010, 25:195-201.
136. Grodzicki M., Kotulski M., Leonowicz D., Zieniewicz K., Krawczyk M. Results of treatment of acute liver failure patients with use of the prometheus FPSA system. Transplant. Proc. 2009, 41:3079-3081.
137. Carpentier B., Gautier A., Legallais C. Artificial and bioartificial liver devices: present and future. Gut 2009, 58:1690-1702.
138. Nyberg S.L. Bridging the gap: advances in artificial liver support. Liver Transpl. 2012, 18(Suppl. 2):S10-S14.
139. Ellis A.J., Hughes R.D., Wendon J.A., Dunne J., Langley P.G., Kelly J.H., Gislason G.T., Sussman N.L., Williams R. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996, 24:1446-1451.
140. Millis J.M., Cronin D.C., Johnson R., Conjeevaram H., Conlin C., Trevino S., Maguire P. Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact. Transplantation 2002, 74:1735-1746.
141. Duan Z., Jing Z., Shaojie X., Ju M.C., Dar H., Brotherton J.D., Maxwell K., Millis M. Interim results of randomized controlled trial of ELAD (TM) in acute on chronic liver disease. Hepatology 2007, 46:233A-330A.
142. Teperman L.W. Efficacy and safety of human cell-based biological liver support system (ELAD ®) in subjects with acute alcoholic hepatitis (AAH) or acute decompensation of cirrhosis (non-AAH). Presentation at the 18th Annual International Congress of the International Liver Transplantation society 2012, (http://vitaltherapies.com/wp-content/uploads/2013/08/2012-VTI-206-Teperman-5-17-12-ILTS2-Corrected.pdf, accessed on January 15th, 2015).
143. Nibourg G.A.A., Hoekstra R., van der Hoeven T., Ackermans M.T., Hakvoort T.B.M., van Gulik T.M., Chamuleau R.A. Effects of acute-liver-failure-plasma exposure on hepatic functionality of HepaRG-AMC-bioartificial liver. Liver Int. 2013, 33:516-524.
144. Gerlach J.C. Bioreactors for extracorporeal liver support. Cell Transplant. 2006, 15(Suppl. 1):S91-S103.
145. Mazariegos G.V., Patzer J.F., Lopez R.C., Giraldo M., Devera M.E., Grogan T.A., Zhu Y., Fulmer M.L., Amiot B.P., Kramer D.J. First clinical use of a novel bioartificial liver support system (BLSS). Am. J. Transplant. 2002, 2:260-266.
146. Demetriou A.A., Brown R.S., Busuttil R.W., Fair J., McGuire B.M., Rosenthal P., Am Esch J.S., Lerut J., Nyberg S.L., Salizzoni M., Fagan E.A., de Hemptinne B., Broelsch C.E., Muraca M., Salmeron J.M., Rabkin J.M., Metselaar H.J., Pratt D., De La Mata M., McChesney L.P., Everson G.T., Lavin P.T., Stevens A.C., Pitkin Z., Solomon B.A. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann. Surg. 2004, 239:660-670.
147. Pan X.-P., Li L.-J. Advances in cell sources of hepatocytes for bioartificial liver. Hepatobiliary Pancreat. Dis. Int. 2012, 11:594-605.
148. Poyck P.P.C., Hoekstra R., van Wijk A.C.W.A., Attanasio C., Calise F., Chamuleau R.A.F.M., van Gulik T.M. Functional and morphological comparison of three primary liver cell types cultured in the AMC bioartificial liver. Liver Transpl. 2007, 13:589-598.
149. Pela I., Seracini D., Donati M.A., Lavoratti G., Pasquini E., Materassi M. Peritoneal dialysis in neonates with inborn errors of metabolism: is it really out of date?. Pediatr. Nephrol. 2008, 23:163-168.
150. Bilgin L., Unal S., Gunduz M., Uncu N., Tiryaki T. Utility of peritoneal dialysis in neonates affected by inborn errors of metabolism. J. Paediatr. Child Health 2014, 50:531-535.
151. Forster V., Signorell R.D., Roveri M., Leroux J.-C. Liposome-supported Peritoneal Dialysis for Detoxification of Drugs and Endogenous Metabolites. Sci Transl Med 2014, 6:258ra141.
152. Chyka P.A., Seger D. Position statement: single-dose activated charcoal. Clin. Toxicol. 1997, 35:721-741.
153. Bosoi C.R., Parent-Robitaille C., Anderson K., Tremblay M., Rose C.F. AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct-ligated rats. Hepatology 2011, 53:1995-2002.
154. Bajaj J.S., Sheikh M.Y., Chojkier M., Balart L., Sherker A.H., Vemuru R., Vierling J.M., Sussman N., Morelli G., Anderson K.E., Scott Harris M., Mullen K.D. AST-120 (spherical carbon adsorbent) in covert hepatic encephalopathy: results of the ASTUTE trial. J. Hepatol. 2013, 58:S84.
155. Wang A.-H., Duan Z.-J., Tian G., Lu D., Zhang W.-J., He G.-H., Fang G.H. The addition of a pH-sensitive gel improves microemulsion stability for the targeted removal of colonic ammonia. BMC Gastroenterol. 2011, 11:50.
156. Romero-Gómez M., Jover M., Del Campo J.A., Royo J.L., Hoyas E., Galán J.J., Montoliu C., Baccaro E., Guevara M., Córdoba J., Soriano G., Navarro J.M., Martínez-Sierra C., Grande L., Galindo A., Mira E., Mañes S., Ruiz A. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann. Intern. Med. 2010, 153:281-288.
157. Ampuero J., Ranchal I., Nuñez D., Díaz-Herrero M.del M., Maraver M., del Campo J.A., Rojas Á., Camacho I., Figueruela B., Bautista J.D., Romero-Gómez M. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS ONE 2012, 7:e49279.
158. Díaz-Herrero M.M., Del Campo J.A., Carbonero-Aguilar P., Vega-Pérez J.M., Iglesias-Guerra F., Periñán I., Miñano F.J., Bautista J., Romero-Gómez M. THDP17 decreases ammonia production through glutaminase inhibition. A new drug for hepatic encephalopathy therapy. PLoS ONE 2014, 9:e109787.
159. Moniaux N., Song H., Darnaud M., Garbin K., Gigou M., Mitchell C., Samuel D., Jamot L., Amouyal P., Amouyal G., Bréchot C., Faivre J. Human hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein cures fas-induced acute liver failure in mice by attenuating free-radical damage in injured livers. Hepatology 2011, 53:618-627.
160. Cunningham S.C., Spinoulas A., Carpenter K.H., Wilcken B., Kuchel P.W., Alexander I.E. AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice. Mol. Ther. 2009, 17:1340-1346.
161. Lee E.K., Hu C., Bhargava R., Rozengurt N., Stout D., Grody W.W., Cederbaum S.D., Lipshutz G.S. Long-term survival of the juvenile lethal arginase-deficient mouse with AAV gene therapy. Mol. Ther. 2012, 20:1844-1851.
162. Cunningham S.C., Kok C.Y., Dane A.P., Carpenter K., Kizana E., Kuchel P.W., Alexander I.E. Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery. Mol. Ther. 2011, 19:854-859.
163. Hu C., Tai D.S., Park H., Cantero-Nieto G., Chan E., Yudkoff M., Cederbaum S.D., Lipshutz G.S. Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy. Gene Ther. 2014, 10.1038/gt.2014.106.
164. Torres-Vega M.A., Vargas-Jerónimo R.Y., Montiel-Martínez A.G., Muñoz-Fuentes R.M., Zamorano-Carrillo A., Pastor A.R., Palomares L.A. Delivery of glutamine synthetase gene by baculovirus vectors: a proof of concept for the treatment of acute hyperammonemia. Gene Ther. 2014, 22:58-64.
165. Sokal E.M. Treating inborn errors of liver metabolism with stem cells: current clinical development. J. Inherit. Metab. Dis. 2014, 37:535-539.
166. Najimi M., Khuu D.N., Lysy P.A., Jazouli N., Abarca J., Sempoux C., Sokal E.M. Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes?. Cell Transplant. 2007, 16:717-728.
167. Khuu D.N., Nyabi O., Maerckx C., Sokal E., Najimi M. Adult human liver mesenchymal stem/progenitor cells participate in mouse liver regeneration after hepatectomy. Cell Transplant. 2013, 22:1369-1380.
168. Sokal E.M., Stéphenne X., Ottolenghi C., Jazouli N., Clapuyt P., Lacaille F., Najimi M., de Lonlay P., Smets F. Liver engraftment and repopulation by in vitro expanded adult derived human liver stem cells in a child with ornithine carbamoyltransferase deficiency. JIMD Rep. 2014, 13:65-72.
169. Defresne F., Tondreau T., Stéphenne X., Smets F., Bourgois A., Najimi M., Jamar F., Sokal E.M. Biodistribution of adult derived human liver stem cells following intraportal infusion in a 17-year-old patient with glycogenosis type 1A. Nucl. Med. Biol. 2014, 41:371-375.
170. Krisper P., Haditsch B., Stauber R., Jung A., Stadlbauer V., Trauner M., Holzer H., Schneditz D. In vivo quantification of liver dialysis: Comparison of albumin dialysis and fractionated plasma separation. J. Hepatol. 2005, 43(3):451-457.